Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Jul
28
Today In Oncology
Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E-Positive Differentiated Thyroid Cancer
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody
Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types
Avatrombopag Manages Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancer
Proton Pump Inhibitor, Antibiotic Exposure Linked to Worse Durvalumab Outcomes in Unresectable Stage III NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo